Medivir Gains on Combination Hepatitis Study: Stockholm Mover

Medivir AB (MVIRB), a Swedish medical research company, rose the most in over two weeks in Stockholm trading after the company said it will perform a mid-stage combination study with its hepatitis C treatment simeprevir.

The shares rose as much as 4.7 percent, the biggest jump since Sept. 3. Medivir had increased 4 percent to 72 kronor as of 12:07 p.m. local time.

The aim of the phase IIa study is to see how many patients, suffering from chronic hepatitis C infection of genotype 1a or 1b, will be virus free 12 weeks after treatment, Stockholm-based Medivir said today in a statement. Simeprevir, which is developed jointly with Johnson & Johnson’s Janssen Research & Development Ireland (JNJ), will be combined with Janssen’s non- nucleoside inhibitor TMC647055.

“This study is in line with Medivir’s and Janssen’s strategy to evaluate different combination possibilities with simeprevir for interferon-free HCV treatments,” Medivir’s head of Research and Development Charlotte Edenius said in the statement. “This will broaden our understanding of simeprevir.”

Simeprevir, or TMC435, is currently undergoing a late stage study for treatment of chronic hepatitis C, Medivir said.

To contact the reporter on this story: Janina Pfalzer in Stockholm at jpfalzer@bloomberg.net.

To contact the editor responsible for this story: Christian Wienberg at cwienberg@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.